Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Non-Current Assets (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Non-Current Assets data on record, last reported at -$32.5 million in Q2 2025.

  • For Q2 2025, Non-Current Assets changed N/A year-over-year to -$32.5 million; the TTM value through Jun 2025 reached $107.4 million, changed N/A, while the annual FY2024 figure was $38.9 million, 19.48% down from the prior year.
  • Non-Current Assets reached -$32.5 million in Q2 2025 per SNTI's latest filing, down from $38.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $230.1 million in Q1 2022 and bottomed at -$32.5 million in Q2 2025.
  • Average Non-Current Assets over 5 years is $94.3 million, with a median of $68.3 million recorded in 2022.
  • The widest YoY moves for Non-Current Assets: up 114.23% in 2022, down 74.59% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $36.5 million in 2021, then skyrocketed by 114.23% to $78.2 million in 2022, then crashed by 38.27% to $48.3 million in 2023, then dropped by 19.48% to $38.9 million in 2024, then plummeted by 183.64% to -$32.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$32.5 million in Q2 2025, $38.9 million in Q4 2024, and $48.3 million in Q4 2023.